Recently, Lumigenex actively participated in the ADLM 2025 exhibition held in the United States. As a highly watched enterprise in the industry, we made a brilliant appearance at this exhibition, attracting the attention of numerous visitors. At this exhibition, we brought the POCT series of dry biochemical analyzers and a number of newly launched products, presenting innovative solutions to the global medical industry.​

In terms of the POCT series of dry biochemical analyzers, we have been committed to providing efficient and accurate equipment for medical testing. Based on advanced dry chemical detection technology, the dry biochemical analyzer can quantitatively determine various biochemical indicators in body fluids such as blood and urine, including blood glucose, blood lipids, liver function, and kidney function, through the direct biochemical reaction between solid-phase carrier reagents and the components to be tested in the sample, and then using optical technologies such as reflectance photometry and transmission turbidimetry. It provides a key basis for clinical diagnosis.​

The newly launched LB-100 Total F became a focus product at the exhibition with its unique design and powerful functions. It can realize rapid detection of multiple indicators, greatly improving detection efficiency. Its non-invasive detection feature reduces the pain of patients during the detection process. At the same time, accurate detection results can be obtained in 15 minutes, winning valuable time for clinical diagnosis. It performs exceptionally well in detecting the urine microalbumin/creatinine ratio (ACR) and glycated hemoglobin, which is of great significance for the early screening and monitoring of chronic diseases such as diabetic nephropathy.​

The co-appearing LTRIC-300 and LTRIC-600 also showed extraordinary performance. They have the advantages of being compact and portable, capable of multi-parameter detection, and easy to maintain. They can play an important role both in primary medical institutions and in emergency rescue scenarios. The instrument's design without liquid path and maintenance-free reduces failures caused by liquid path problems, and multiple quality controls ensure the accuracy of detection results. The use of dry-type single-use test cards effectively avoids iatrogenic exposure and provides a guarantee for the safety of medical testing.​

In addition, we also launched rapid test strips for uric acid and creatinine, further enriching the detection product line. These test strips are easy to operate, can quickly and accurately detect the levels of uric acid and creatinine, and provide a convenient means for evaluating kidney health.​

At the ADLM 2025 exhibition, Lumigenex showed the world its strength in the field of medical testing with innovative products and professional services. We will continue to uphold the spirit of innovation, constantly develop better products, and contribute to promoting the development of the global medical industry.